earnings
confidence high
sentiment positive
materiality 0.80
Gilead Q3 2025: Non-GAAP EPS $2.47 beats $2.02; product sales ex-Veklury up 4% to $7.1B; guidance raised
GILEAD SCIENCES, INC.
2025-Q3 EPS reported
$5.04
revenue$21,518,000,000
- GAAP diluted EPS $2.43 vs $1.00; non-GAAP EPS $2.47 vs $2.02; revenue $7.8B up 3% YoY.
- Biktarvy sales up 6% to $3.7B; Descovy up 20% to $701M; HIV portfolio up 4% to $5.3B.
- Veklury down 60% to $277M; Cell therapy down 11% to $432M; Trodelvy up 7% to $357M.
- Full-year product sales guidance raised to $28.4-28.7B; non-GAAP EPS raised to $8.05-8.25.
- Operating cash flow $4.1B; dividends $1.0B; share repurchases $435M in Q3.